José Carlos Jaime-Pérez

José Carlos Jaime-Pérez

Auto-generated profile, based on publicly available information

José Carlos Jaime-Pérez


Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
PAPatrizia Elva Aguilar-Calderón
Patrizia Elva Aguilar-Calderón
LSLorena Salazar-Cavazos
Lorena Salazar-Cavazos
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Evans syndrome (ES) is a rare and chronic autoimmune disease characterized by autoimmune hemolytic anemia and immune thrombocytopenic purpura with a positive direct anti-human globulin test. It is classified as primary and secondary, with the frequency in patients with autoimmune hemolytic anemia being 37%–73%. It predominates in children, mainly due to primary immunodeficiencies or autoimmune lymphoproliferative syndrome. ES during pregnancy is associated with high fetal morbidity, including severe hemolysis and intracranial bleeding with neurological sequelae and death. The clinical presentation can include fatigue, pallor, jaundice and mucosal bleeding, with remissions and exacerbations during the person’s lifetime, and acute manifestations as catastrophic bleeding and massive hemolysis. Recent molecular theories explaining the physiopathology of ES include deficiencies of CTLA-4, LRBA, TPP2 and a decreased CD4/CD8 ratio. As in other autoimmune cytopenias, there is no established evidence-based treatment and steroids are the first-line therapy, with intravenous immunoglobulin administered as a life-saving resource in cases of severe immune thrombocytopenic purpura manifestations. Second-line treatment for refractory ES includes rituximab, mofetil mycophenolate, cyclosporine, vincristine, azathioprine, sirolimus and thrombopoietin receptor agonists. In cases unresponsive to immunosuppressive agents, hematopoietic stem cell transplantation has been successful, although it is necessary to consider its potential serious adverse effects. In conclusion, ES is a disease with a heterogeneous course that remains challenging to patients and physicians, with prospective clinical trials needed to explore potential targeted therapy to achieve an improved long-term response or even a cure.

29 January 2011 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
PCPerla R. Colunga-Pedraza
Perla R. Colunga-Pedraza
CGCynthia D. Gómez-Ramírez
Cynthia D. Gómez-Ramírez
CGCesar Homero Gutierrez-Aguirre
Cesar Homero Gutierrez-Aguirre
OCOlga G. Cantú-Rodríguez
Olga G. Cantú-Rodríguez
DGDavid Gómez-Almaguer
David Gómez-Almaguer

6 March 2015 in The Oncologist
Verified
Journal Article
Open access
PDF file
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
AHAlberto Carlos Heredia-Salazar
Alberto Carlos Heredia-Salazar
OCOlga G. Cantú-Rodríguez
Olga G. Cantú-Rodríguez
CGCesar Homero Gutierrez-Aguirre
Cesar Homero Gutierrez-Aguirre
CMCesar Daniel Villarreal-Villarreal, MD
Cesar Daniel Villarreal-Villarreal, MD
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Background and Objective.: Hematopoietic stem cell transplantation (HSCT) in developing countries is cost-limited. Our primary goal was to determine the cost structure for the HSCT program model developed over the last decade at our public university hospital and to assess its clinical outcomes. Materials and Methods.: Adults and children receiving an allogeneic hematopoietic stem cell transplant from January 2010 to February 2011 at our hematology regional reference center were included. Laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization costs were scrutinized to calculate the total cost for each patient and the median cost for the procedure. Data regarding clinical evolution were incorporated into the analysis. Physician fees are not charged at the institution and therefore were not included. Results.: Fifty patients were evaluated over a 1-year period. The total estimated cost for an allogeneic HSCT was $12,504. The two most expensive diseases to allograft were non-Hodgkin lymphoma ($11,760 ± $2,236) for the malignant group and thalassemia ($12,915 ± $5,170) for the nonmalignant group. Acute lymphoblastic leukemia ($11,053 ± 2,817) and acute myeloblastic leukemia ($10,251 ± $1,538) were the most frequent indications for HSCT, with 11 cases each. Median out-of-pocket expenses were $1,605, and 1-year follow-up costs amounted to $1,640, adding up to a total cost of $15,749 for the first year. The most expensive components were drugs and laboratory tests. Conclusion.: Applying the cost structure described, HSCT is an affordable option for hematological patients living in a developing country.

1 January 2019 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
GGGisela García-Arellano
Gisela García-Arellano
JHJosé Luis Herrera-Garza
José Luis Herrera-Garza
LMLuis Javier Marfil-Rivera
Luis Javier Marfil-Rivera
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Heterogeneity regarding clinical and laboratory findings at diagnosis of acute lymphoblastic leukemia exists. The frequency of complete blood count abnormalities and its combinations, symptoms and physical findings were investigated in Hispanic children from an open population at the diagnosis of acute lymphoblastic leukemia. The patient charts and electronic records of under 16-year-old children diagnosed with acute lymphoblastic leukemia over 10 years at a regional hematology center of a university hospital were analyzed to retrieve data concerning the complete blood count at first evaluation. Type and distribution of abnormal data, frequency of symptoms and physical findings at presentation were documented. The records of 203 children aged 0-15 years diagnosed with acute lymphoblastic leukemia from 2006 to 2016 were revisited. The results of the blood workup showed a median white blood cell count of 7120 × 109/L (range: 450-600,000 × 109/L), and a median hemoglobin concentration of 7.5 g/dL (range: 2.4-15.3 g/dL), whereas the median platelet count was 47,400 × 109/L (range: 4000-544,000 × 109/L). Leukocytosis and leukopenia were present in 36.6% and 36.1% of cases, respectively; anemia was diagnosed in 82.9% children. The order of frequency for major clinical symptoms was fatigue 62%, fever 60%, bone and joint pain 39%, hyporexia 33% and weight loss 21%, while main physical findings were hepatomegaly 78%, splenomegaly 63%, lymphadenopathy 57%, pallor 48%, and purpura 30%. Data differing from those classically expected at diagnosis of acute lymphoblastic leukemia in children were documented in a cohort of Hispanic children over one decade with a wide spectrum of complete blood count abnormalities, forms of presentation and frequency of physical findings.

1 September 2005 in Archives of Medical Research
Verified
Journal Article
Closed access
JJJose C. Jaime-Perez
Jose C. Jaime-Perez
JHJose L. Herrera-Garza
Jose L. Herrera-Garza
DGDavid Gomez-Almaguer
David Gomez-Almaguer

27 January 2009 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JJJosé Carlos Jaime‐Pérez
José Carlos Jaime‐Pérez
LRLaura N. Rodríguez‐Romo
Laura N. Rodríguez‐Romo
OGOscar González‐Llano
Oscar González‐Llano
ACAdrián Chapa‐Rodríguez
Adrián Chapa‐Rodríguez
DGDavid Gómez‐Almaguer
David Gómez‐Almaguer
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.